As scientific output grows, the risk of a promising drug getting lost increases, but advances in artificial intelligence and machine learning may prevent that.
Elizabeth Laws leads Sanofi’s inflammation and immunology development pipeline to test the first oral TNFR1 inhibitor for rheumatoid arthritis and psoriasis.